Investment Rating - The report gives an "Overweight" rating for the industry, indicating a positive outlook compared to the overall market performance [48]. Core Insights - The report highlights that Innovent Biologics (诺诚健华) achieved a revenue of 381 million yuan in Q1 2025, representing a year-on-year growth of 129.9%, and turned a profit with a net profit of 18 million yuan [2][10]. - The report also notes that the healthcare sector, particularly in pharmaceuticals, is experiencing significant growth, with key players like JD Health and Innovent Biologics showing strong performance [2][10]. - The report emphasizes the ongoing commercialization of innovative drugs, which is expected to lead to profitability turning points for several companies in the sector [14]. Summary by Sections 1. Pharmaceutical Industry Updates - JD Health reported a revenue of 16.645 billion yuan in Q1 2025, a 25.5% increase year-on-year, with a net profit of 934 million yuan, up 4.6% [10]. - Innovent Biologics' core products are seeing increased sales, prompting an upward revision of the full-year sales guidance [2][10]. - The report mentions several companies making significant advancements, including Heng Rui Medicine's upcoming IPO and Stone Pharmaceutical's licensing agreement for irinotecan liposome injection in the U.S. [11]. 2. Overseas Pharmaceutical Developments - AbbVie received FDA approval for its c-Met ADC, EMRELIS, for treating advanced non-small cell lung cancer [12]. - Novo Nordisk announced a collaboration with Septerna for the development of oral small molecule drugs targeting obesity and type 2 diabetes, with potential payments reaching up to 2.2 billion USD [12]. - The report highlights the successful Phase III trial of Novo Nordisk's long-acting growth hormone, Sogroya, showing non-inferiority to daily growth hormone Norditropin [12][13]. 3. Investment Recommendations - The report suggests focusing on innovative drug companies that are expected to see continued growth and potential profitability, including companies like BeiGene, Innovent Biologics, and others [14]. - It also recommends attention to pharmaceutical companies that are progressively advancing their innovative pipelines, such as Hansoh Pharmaceutical and China National Pharmaceutical Group [14]. 4. Education Sector Updates - The education index saw a 5.9% increase, outperforming the Hang Seng National Enterprises Index by 2.9 percentage points [20]. - The report suggests focusing on Chinese education companies, particularly New Oriental and TAL Education, as they are expected to benefit from the normalization of regulatory policies [22].

Core Viewpoint - The company, Innocare Pharma, is holding an investor briefing on May 26, 2025, to discuss its Q1 2025 financial results and operational performance [1][2]. Group 1: Meeting Details - The investor briefing is scheduled for May 26, 2025, from 9:00 AM to 10:00 AM [2]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website: http://roadshow.sseinfo.com/ [2]. - The format of the meeting will be an online interactive session [1][2]. Group 2: Participation Information - Investors can submit questions from May 19, 2025, to May 23, 2025, by visiting the Roadshow Center's website or emailing IR@innocarepharma.com [1][3]. - The company will address commonly asked questions during the briefing [1][3]. Group 3: Attendees - Key attendees include Dr. Jisong Cui (Chairman and CEO), Ms. Hulan (Independent Non-Executive Director), Mr. Fu Xin (CFO), and Ms. Yuan Bei (Domestic Information Disclosure Representative) [2].

| A | 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2025-017 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 26 日(星期一)上午 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 独立非执行董事：胡兰女士 投资者可于 2025 年 5 月 19 日（星期一）至 5 月 23 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答 诺诚健华医药有限公司（以下简称"公 ...

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 381 million yuan, representing a year-on-year increase of 129.92%, with a net profit attributable to shareholders of 17.97 million yuan and a non-GAAP net profit of 1.59 million yuan [1] - The revenue from Obinutuzumab reached 311 million yuan in Q1 2025, showing an increase of 89.22%, driven by the rapid growth in demand for the exclusive MZL indication [1] Group 2: Product Development and Pipeline - The company is advancing multiple innovative drug developments, with Tafasitamab expected to receive approval in the first half of 2025, enhancing the product pipeline in the hematological oncology field [2] - The global Phase III clinical study for Obinutuzumab in PPMS/SPMS is expected to complete the first patient enrollment within 2025, while the ITP indication is in Phase III and is anticipated to submit an NDA in the first half of 2026 [1][2] - The company has submitted an NDA for the pan-TRK inhibitor zurletrectinib (ICP-723), which has been granted priority review status [2] Group 3: Revenue Forecast and Valuation - The company has adjusted its revenue forecasts, expecting revenues of 1.442 billion yuan, 1.737 billion yuan, and 2.128 billion yuan for 2025 to 2027, with year-on-year growth rates of 42.8%, 20.5%, and 22.5% respectively [3] - The projected net profit attributable to shareholders for the same period is expected to be -259 million yuan, -214 million yuan, and -213 million yuan, leading to corresponding PE ratios of -140.7, -169.7, and -170.8 [3]

Group 1 - BeiGene reported Q1 2025 revenue of 8.048 billion yuan, a 50.2% increase from 5.359 billion yuan in the same period last year, with a net loss of 94.503 million yuan, significantly reduced from a loss of 1.908 billion yuan year-on-year [1] - Innovent Biologics disclosed Q1 2025 revenue of 381 million yuan, a year-on-year increase of 129.92%, with a net profit of 18 million yuan, up 112.62% year-on-year, marking a turnaround to profitability [1] - The Hong Kong innovative drug sector shows improving fundamentals, with the Hong Kong innovative drug index's P/E ratio dropping from 64 times on February 21 to 24 times on May 16, indicating a strong value proposition for investors [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with a 90% weight in innovative drug companies, poised to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) tracks a broader innovative drug index, including leading companies in the innovative drug industry chain, expected to benefit from AI advancements and new healthcare policies [2] Group 3 - CICC believes the innovative drug sector demonstrates strong investment value despite market pressures from U.S. tariff policies, as it relies on a knowledge-based payment model, making it less susceptible to short-term impacts [3] - The pricing logic of innovative drugs is centered around long-term product launch and sales expectations rather than current operational fundamentals, providing resilience during market fluctuations [3] - Upcoming international academic conferences, such as ASCO, are expected to boost sentiment in the innovative drug sector, making it a focus for investors from May to June [3]

Core Viewpoint - InnoCare Pharma reported strong financial performance in Q1 2025, with significant revenue growth and a shift to profitability, driven by the sales ramp-up of its key product, orelabrutinib [1][5]. Financial Performance - Q1 2025 revenue reached Rmb381 million, representing a 130% year-over-year increase, while net profit was Rmb18 million, a turnaround from net losses of Rmb142 million in Q1 2024 [1]. - Sales of orelabrutinib amounted to Rmb311 million, reflecting an 89% year-over-year growth [1]. - R&D expenses were Rmb208 million, up 17% year-over-year, and selling expenses reached Rmb114 million, increasing by 27% year-over-year, with the selling expense ratio decreasing by 24.1 percentage points to 30% [1]. - Gross profit margin improved by 5.2 percentage points to 90.5% due to enhanced production efficiency and contributions from business development revenue [1]. - As of March 2025, the company had a cash balance of approximately Rmb7.8 billion [1]. Product Development and Sales Outlook - The sales target for orelabrutinib has been raised from over 30% year-over-year to over 35% year-over-year for 2025, supported by the addition of three indications into the National Reimbursement Drug List (NRDL) and recent NMPA approval for first-line CLL/SLL [1]. - Orelabrutinib is currently undergoing phase III trials for immune thrombocytopenic purpura (ITP) in China, with a new drug application (NDA) expected in the first half of 2026, and phase IIb trials for systemic lupus erythematosus (SLE) with data readouts anticipated in Q4 2025 [1]. Other Product Developments - The Biologics License Application (BLA) for tafasitamab for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) was accepted by the NMPA, with approval expected in 2025 [2]. - ICP-248 (BCL-2) is in phase III trials in combination with orelabrutinib for first-line CLL/SLL, and has received breakthrough therapy designation (BTD) from the CDE for r/r mantle cell lymphoma (MCL) [2]. - The company is actively developing pipelines for autoimmune diseases, including phase III trials for atopic dermatitis (AD) and psoriasis, and has pre-clinical assets targeting IL-17 [3]. ADC Product Development - The company filed an Investigational New Drug (IND) application for its first antibody-drug conjugate (ADC) product, ICP-B794 (B7-H3 ADC), which has shown promising therapeutic effects and safety in preclinical studies [4]. Investment Outlook - The EPS forecast has been adjusted from -Rmb0.21 to -Rmb0.19 for 2025, from -Rmb0.06 to -Rmb0.05 for 2026, and a forecast of Rmb0.16 for 2027 [5]. - The target price has been raised from HK$10.0 to HK$11.8, indicating a 25% upside potential, and the company maintains a BUY rating [5].

Group 1: Financial Data Overview - In April 2025, new social financing amounted to approximately 1.16 trillion, an increase of 1.22 trillion year-on-year, with stock social financing growing by 8.7% year-on-year, and a month-on-month increase of 0.3 percentage points [11][13][14] - New credit in April was 280 billion, a decrease of 450 billion year-on-year, reflecting a weak demand in the corporate sector and a low retail demand under pressure [11][13][17] - M1 grew by 1.5% year-on-year, while M2 increased by 8.0%, with a month-on-month rise of 1 percentage point [11][13][17] Group 2: Robotics Industry Insights - The core of embodied intelligence lies in algorithms, which are divided into upper-level "brain" for task planning and decision-making, and lower-level "cerebellum" for real-time motion planning and joint control [12][10] - Data quality and diversity are crucial for algorithm performance, with real data being the primary source, supplemented by synthetic data generated through simulation platforms [12][10] - The control system serves as the foundation for embodied intelligence, with the brain executing complex algorithms and the cerebellum controlling robot movements, primarily using SoC chips [12][10] Group 3: Company Performance Highlights - Nocera's revenue in Q1 2025 increased by 130% year-on-year, reaching 381 million, with a net profit of 18 million, compared to a net loss of 142 million in the same period last year [16][19] - The sales of the core product, Acalabrutinib, grew by 89% to 311 million in Q1 2025, leading to an upward revision of the annual sales target from over 30% to over 35% growth [16][19] - The company is actively expanding its pipeline for autoimmune diseases and has submitted an IND application for its first ADC product [19][16]

Investment Rating - The industry investment rating is "Strongly Outperform" [1] Core Insights - The pharmaceutical sector shows continuous improvement signals in performance for 2024 and Q1 2025, with overall profitability on the rise. Despite short-term pressures, segments like chemical pharmaceuticals and medical consumables are performing well. The sector's valuation remains at historical lows, indicating significant upside potential [3][23][26] Summary by Sections 1. Performance Review for 2024-2025 Q1 - The pharmaceutical sector's overall revenue growth rates declined by 1% and 4.3% respectively for 2024 and Q1 2025, with net profit growth rates down by 13.1% and 9.2%. The decline is attributed to medical restructuring and price reductions from centralized procurement [7][19] - Despite the challenges, segments such as chemical pharmaceuticals and raw materials have shown resilience, benefiting from policy support and rising raw material prices [18] 2. Innovative Drug Industry Chain - The innovative drug sector is supported by comprehensive policies, with a notable acceleration in commercialization. The recovery in overseas investment and demand is evident, leading to improved order growth for CXO and upstream companies [3][29] - The sector is expected to see high growth in 2024, particularly in oncology, autoimmune diseases, weight loss, Alzheimer's, NASH, hair loss, and hepatitis B [3][29] 3. Traditional Chinese Medicine and Medical Services - The out-of-hospital consumption sector, including pharmacies and OTC, is anticipated to recover from inventory issues and weak consumption, with growth expected in 2025. The sector is also witnessing a wave of mergers and acquisitions led by state-owned enterprises [3][29] 4. Medical Devices - The medical device sector faced revenue and profit growth pressures in 2024 due to hospital restructuring and procurement delays. However, with the easing of these pressures, a rebound is expected in 2025, particularly in domestic replacements and AI+medical applications [3][29] 5. Beneficiary Stocks - Recommended stocks include Aladdin, Kanglong Chemical, Rongchang Bio, Nocare, Maipu Medical, Yihua Jiaye, MicroPort Scientific, Yirui Technology, Yifeng Pharmacy, Dazhenglin, and Meinian Health [3][29] 6. Fund Allocation - The public fund allocation in the pharmaceutical sector is at a historical low of 9.2% in Q1 2025, down from 13.7% at the end of 2023. This is expected to reverse as the impact of medical anti-corruption fades and policy support increases [26][27]

Core Insights - The wealth management sector of securities firms is showing performance elasticity against the backdrop of a recovering capital market, with a reported net income of 115.15 billion yuan in 2024, marking a year-on-year increase of 16.98% [1] - Despite growth, the sector faces challenges such as market volatility, declining fees, intensified competition, and increased complexity in compliance management [1] - The demand for specialized services in equity investment and asset allocation is driving the transition of wealth management towards a buyer advisory model, termed as phase 3.0 [1][2] Company Overview - As of the end of 2024, the company operates nearly 70 branches nationwide, serving approximately 1.8 million clients and managing assets close to 150 billion yuan [2] - The wealth management business has evolved through three stages: from transaction service (1.0), to product sales (2.0), and currently to asset allocation services (3.0) [2] Wealth Management Strategy - The company launched the "Yue Guanjia" wealth management brand, which includes three service systems: investment advisory, private wealth, and corporate services [3] - The strategic framework for wealth management is summarized as "two foundations + three directions," focusing on stabilizing brokerage and margin trading while innovating in digital finance, private wealth, and institutional business [5] Organizational Structure - In Q1 2025, the company restructured its wealth management division from three departments to five, enhancing the focus on client management and professional support [6] - The company emphasizes building a licensed investment advisory team, with plans to recruit and train talent through partnerships with educational institutions [6] Digital Financial Innovations - The establishment of a digital finance department aims to provide integrated, online, and intelligent services to retail clients [7] - The company is developing a comprehensive internet advisory product and service system, integrating educational content, research reports, and curated investment portfolios [7] Private Wealth Business - The private wealth business is in its early stages, targeting affluent, high-net-worth, and ultra-high-net-worth clients with tailored products and services [8] - The company plans to enhance its product offerings and service capabilities by recruiting additional private wealth advisors and establishing a collaborative organizational structure [8] Corporate Services - The "Yue Guanjia Corporate Services" aims to provide comprehensive financial services to corporate clients, leveraging partnerships with various business sectors [9][10] - The corporate finance business has seen significant growth, with a year-on-year increase of over 40% in scale and over 50% in new institutional clients [10] AI and Technology Integration - The "AI Investment Advisor Assistant" is a tool developed to enhance investment advisory services, utilizing advanced AI models for market analysis and client engagement [11] - The company plans to expand its AI applications across various business lines, focusing on efficiency, scenario penetration, and ecosystem empowerment [11] Challenges and Strategic Focus - Key challenges for the wealth management sector include strategic choices, organizational structure, product selection, customer acquisition, and operational management [12][13] - The company aims to address these challenges by refining its strategic direction, enhancing organizational vitality, and optimizing customer relationship management [12][13]

截至2025年5月15日 10:15，恒生医疗保健指数(HSHCI)上涨0.11%，成分股远大医药(00512)上涨6.15%，诺诚健华(09969)上涨4.36%，巨子生物(02367)上涨 3.75%，药师帮(09885)上涨2.38%，健康之路(02587)上涨1.83%。恒生医疗ETF(513060)上涨0.21%， 冲击3连涨。最新价报0.48元。流动性方面，恒生医疗 ETF盘中换手2.77%，成交2.74亿元。拉长时间看，截至5月14日，恒生医疗ETF近1月日均成交12.54亿元，排名可比基金第一。 2025年5月12日，商务部公布了中美日内瓦经贸会谈联合声明。声明指出：中美双方近期会将4月2日相关的34%关税分为24%（暂缓90天）和10%，中国还将 暂停或取消自2025年4月2日起针对美国的非关税反制措施。中美双方未来还会建立机制，继续就经贸关系进行协商。 湘财证券指出，中美关税的缓和有利于国内医疗器械降低生产成本，扩大海外市场份额。而对于CXO，政策边际缓和有望迎来估值修复。我们看好医疗服 务行业，建议关注出口产业链。 恒生医疗ETF紧密跟踪恒生医疗保健指数，恒生医疗保健指数提供一项市场参考 ...